George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
My take on this is that issues are geopolitical. That’s no comfort though.
I re-read the original RNS. I was thinking there might be a way for Bosch to progress without Weichai but I can’t see it. Weichai are in both JVs.
I’m hoping there is a plan B. If there is it’s well under wraps but I suppose it would be until it is announced unless of course to put pressure on Weichai.
Thanks Tennents.
This may be pretty big news. I’m not absolutely certain on the technical side but the 30MEP bar is a step up in pressure from the 20 MEP bar they produced previously. The 30MEP process underpins the larger 10MW modules that form the basis of the 200MW RWE contract.
Today plug shot up 14% on basis of 3 orders signed based on their current 5MW system- what they describe as the « largest in the world ». If todays ITM announcement signals that they are well on the way to delivering 10MW modules then this is huge. As per my previous post if ITM is entering a new phase of starting to deliver at scale then it’s hugely undervalued IMO.
Https://theenergyst.com/itm-power-raises-250-million-to-boost-electrolyser-output/
This is a historic article but illustrates how much ITM partners valued the company and technology.
While there have been serious supply side and performance issues this last 12 months Linde clearly haven’t written off ITM- they placed a 200MW order.
Worth noting also that competition haven’t excelled on the delivery side yet- plug delivered 66MW in first 3 months 2023.
Much of the Linde cash raise is still there and company currently valued at little more than cash in hand. In addition today has seen 14bn committed by Japanese companies to consortia that ITM have previously done business with. Bottom line is huge potential upside here if ITM under Schultz can deliver at scale.
https://www.world-nuclear-news.org/Articles/Coalition-applies-for-US-hydrogen-hub-funding
No guarantees this would involve ITM but interesting
https://www.independent.co.uk/news/ap-michigan-gretchen-whitmer-norwegian-detroit-b2331833.html?amp
Nel and GM collaboration appears to be bearing fruit. I’m hoping DS is correct that ITM will be firing on all cylinders and won’t miss out on big opportunities.
I’m liking how focussed he is on the larger electrolysers. I
https://www.independent.co.uk/news/ap-michigan-gretchen-whitmer-norwegian-detroit-b2331833.html?amp
Seems to be a pretty huge vote of confidence from GM and a deepening of US relationship.
I’m with you Dudio. The emphasis here was on focussed investigator led studies (plural). Usually in investigator led studies the pharma company will provide the investigational agent. The studies are en on a much lower cost than pharma sponsored studies. They do tend to rely on non-pharma funding eg MRC. Downside is timescale and ownership of results: we saw that with ACTIV2 when positive results took a long time to be fully released to SNG.
The suggestion was that these should start in q2/3 23 which would imply that they were pretty much agreed in principle but perhaps going through or about to go through ethics/R&D at the sites.
I’m not convinced we’ll see any shift in SP until these start to be confirmed in the next 3-6 months hopefully. I get the feeling that some may be very focussed eg immunosuppressed, possibly those with interferon deficiency. That may allow registration with the bigger SPRINTER and other P2s used as really good evidence of safety- although results non-significant statistically they central estimates were towards benefit in pretty much every aspect measured.
Traders may well have some ups and downs between now and then but I think investors can take heart. I don’t think a big fund raise for further P3 likely.
https://www.lancs.live/news/uk-world-news/arcturus-covid-latest-ukhsa-reports-26758201?int_source=amp_continue_reading&int_medium=amp&int_campaign=continue_reading_button#amp-readmore-target
5 desths out of 105 Arcturus sequences. Clearly this can’t be taken as a « fatality rate » as cases sequenced not representative but difficult to see this as anything other than potentially worrying.
https://www.h2-view.com/story/usnc-hyundai-sk-es-target-nuclear-hydrogen-production-in-south-korea/
This type of deal is Ceres core market for SOEC.
From memory the JVs didn’t cover SOEC. It would be helpful if next partner wasn’t so caught up in geopolitical issues.
https://www.biorxiv.org/content/10.1101/2023.04.12.536671v1
This link was re-tweeted by Eric Fiegel Ding- eminent Harvard epidemiologist who posts on Covid. SNG is a paradigm shift in anti-viral scientific thinking. It needs publicised as much as possible.
This appears to be a summary of relevant data, publications and the odd opinion to date.
Of interest the first reference is to P Monks forthcoming presentation in May which neatly summarises the evidence to date.
https://twitter.com/rickabright/status/1645546055180722180?s=46&t=lUUs8mZ3DzN0LONpU_7P4w
It took 2 years but with funding now unlocked SNGs future could be bright (forgive the pun)
Not sure if this bears any relationship to Weichai or Ceres but fairly interesting
https://www.gizmochina.com/2023/04/10/1000-km-liquid-hydrogen-system-weishi-energy/
For clarity on dexa- harmful for those not on oxygen. Marginal benefit for those needing low flow oxygen. Biggest benefit for those on high flow oxygen or mechanical ventilation so overlaps a little with SNG. Rationale is early in infection it is viral replication phase and later immune “overdrive” phase. Immunosuppressant therapy, like anti-IL6 and dex work later, antivirals like paxlovid and mabs (all of which are out of action due to Covid immune evolution) work earlier. Synairgen is kind of in the middle- works a little later than paxlovid. Host directed antivirals have their place.
In case im accused of ramping- I’m still here and invested because this is my assessment of the evidence to date.
I don’t think this is directly competing with SNGs potential place in therapy. This is a late stage treatment for people on mechanical ventilation or ECMO. SNGs therapeutic window is likely a little earlier- breathless or needing oxygen.
They will have had a higher event rate in these sickest patients, hence some statistically significant results on a trial only slightly bigger than sprinter. Sprinter was grossly underpowered, with hindsight. Synairgen gambled on the shorter stay primary endpoint and that proved to be a mistake. We’re all wise with hindsight.
In many ways SNG remains a binary outcome. They’ll demonstrate efficacy - and signals strong over several P2 and 1 underpowered P3 - or disappear.
The media may be tired of reporting on Covid but it is still very much a problem.
624 deaths in week to 23rd March in England and Wales with Covid on death certificate, main cause in over 2/3 of those.
Excess mortality at 13% above 5year pre-pandemic average.
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovisional/weekending24march2023
Atanasof
https://highviewpower.com/news_announcement/uk-energy-security-undermined-by-lack-of-energy-storage-capabilities/
We already have an abundance of energy at times. As renewables ramped up this will increase exponentially……
Hydrogen has a big future though we may still be 2 years from hydrogen electrolysis companies break even. Sales ramp up generally is ahead of the most optimistic projections from 3 years ago and the big hike on SPs of hydrogen companies.
The big question is whether or not an individual company can deliver. If Ceres inks the deal with Bosch and Weichai there is a clear route to profitability. Not so sure though if for political reasons that falls through.